Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas

Modern Pathology

Volumn 26, Issue 11, 2013, Pages 1451-1460

  Acs, Geza ^a,b   Kiluk, John ^a   Loftus, Loretta ^a   Laronga, Christine ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Ruffolo Hooper and Associates   (United States)

Author keywords

breast cancer; Mammostrat; Oncotype DX; risk estimation

Indexed keywords

CYTOKERATIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; RNA;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER MORPHOLOGY; CANCER RECURRENCE; CANCER TISSUE; CARCINOMA CELL; CELL PROLIFERATION; CORRELATION ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE INVASIVE BREAST CARCINOMA; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTERMETHOD COMPARISON; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; RNA EXTRACTION;

BREAST NEOPLASMS; CELL PROLIFERATION; DECISION SUPPORT TECHNIQUES; FEMALE; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KERATINS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887043466     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.88     Document Type: Article

References (43)

1. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009;6:718-730.
2. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010;220:263-280.
3. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826. (Pubitemid 40051905)
4. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
6. van de Vijver MJ, He YD, Van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. (Pubitemid 35461656)
7. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-272. (Pubitemid 43264710)
8. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 2005;365: 671-679. (Pubitemid 40260888)
9. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-1300. (Pubitemid 44706932)
10. Ring BZ, Seitz RS, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006;24: 3039-3047. (Pubitemid 46638938)
11. Ross DT, Kim CY, Tang G, et al. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res 2008;14:6602-6609.
12. Bartlett JM, Thomas J, Ross DT, et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 2010;12:R47.
13. Esteva FJ, Sahin AA, Cristofanilli M, et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005;11:3315-3319. (Pubitemid 40627881)
14. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734. (Pubitemid 46622311)
15. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009;7:122-192.
16. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312. (Pubitemid 350232263)
17. Allison KH, Kandalaft PL, Sitlani CM, et al. Routine pathologic parameters can predict Oncotype DX(TM) recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 2011;131:413-424.
18. Baehner F, Quale C, Pomeroy C, et al. Biopsy cavities in breast cancer specimens: their impact on quantitative RT-PCR gene expression profiles and recurrence risk assessment [abstract]. Mod Pathol 2008;22: 28A-29AA.
19. Acs G, Esposito NN, Kiluk J, et al. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. Mod Pathol 2012;25:556-566.
20. Pinder SE, Elston CW, Ellis IO. Invasive carcinoma-usual histologic types, In: Elston CW, Ellis IO(eds). The Breast, 3 edn. Churchill Livingstone: Edinburgh; 1998, pp 283-337.
21. Page DL, Anderson TJ, Sakamoto G. Infiltrating carcinoma: major histologic types, In: Page DL, Anderson TJ (eds). Diagnostic Histopathology of the Breast. WB Saunders: London; 1987, pp 193-235.
22. Elston CW, Ellis IO. Assessment of histologic grade, In: Elston CW, Ellis IO (eds). The Breast, 3 edn. Churchill Livingstone:: Edinburgh; 1998, pp 365-384.
23. Elston CW, Ellis IO, Goulding H, et al. Role of pathology in the prognosis and management of breast cancer, In: Elston CW, Ellis IO (eds). The Breast. Churchill Livingstone: Edinburgh; 1998, pp 385-433.
24. Blamey RW, Ellis IO, Pinder SE, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007;43:1548-1555. (Pubitemid 46901016)
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002;41:154-161.
26. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010;12:207.
27. Lundin J, Lundin M, Holli K, et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001;19:28-36. (Pubitemid 32063476)
28. Simpson JF, Gray R, Dressler LG, et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000;18:2059-2069. (Pubitemid 30324359)
29. Frkovic-Grazio S, Bracko M. Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. J Clin Pathol 2002;55:88-92. (Pubitemid 34123906)
30. Mirza AN, Mirza NQ, Vlastos G, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235:10-26. (Pubitemid 34062395)
31. Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987;56:489-492. (Pubitemid 17146357)
32. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-1329.
33. Yu K, Lee CH, Tan PH, et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res 2004;64:2962-2968. (Pubitemid 38581389)
34. Lu X, Lu X, Wang ZC, et al. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 2008;108:191-201. (Pubitemid 351311362)
35. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008;26:3153-3158.
36. Henson DE, Ries L, Freedman LS, et al. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991;68:2142-2149.
37. Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 2010;28:99-104.
38. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 2008;26:1-10.
39. Robbins P, Pinder S, de KN, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995;26:873-879.
40. Grimes M, Coad J, Oliviero B, et al. Comparison of Oncotype DX Recurrence Score and standard immunohistochemical prognostic markers [abstract]. Mod Pathol 2007;20:33A.
41. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10:R65.
42. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008;14:5158-5165.
43. Ingber DE. Cancer as a disease of epithelial-mesenchymal interactions and extracellular matrix regulation. Differentiation 2002;70:547-560.